TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01750255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical Care
Description: Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
Study: NCT03065829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention-Control
Description: Wearable sensor technology only viewing biophysical sensor data.
Study: NCT01133964

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dairy proteins
Description: Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dairy proteins
Description: Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: dairy proteins
Description: Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dairy proteins
Description: Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
Study: NCT03026738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior mesh rectopexy
Description: fixation of the rectum anteriorly using laparosopy and polypropylene mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic posterior mesh rectopexy
Description: fixation of the rectum posteriorly using laparosopy and polypropylene mesh
Study: NCT01532141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline (single-dose)
Study: NCT03026738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polypropylene mesh
Description: A strip of polypropylene mesh will be introduced and sutured.
Study: NCT03707275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexa+
Description: Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Arm
Description: This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
Study: NCT01143740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: orally day 1-10 each 28-day cycle, 3 cycles
Study: NCT00129662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial action plan
Study: NCT02672020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omics identity card
Study: NCT03026738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polypropylene mesh
Description: A strip of polypropylene mesh will be introduced and sutured.
Study: NCT04304456

Intervention type: OTHER
Intervention: Treatment
Description: Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
Study: NCT02227576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study: NCT02728427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization using central venous catheter(CVC-2 7F)
Description: Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
Study: NCT02321969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTE (green tea extract)
Description: 6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
Study: NCT02728427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral catheterization using Foley catheter
Description: Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
Study: NCT00096161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given IV
Study: NCT01418508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low protein diet plus α-keto acid
Description: low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: very low protein diet plus α-keto acid
Description: very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
Study: NCT02762227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal high resolution CT
Description: CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Description: CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
Study: NCT03849573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OncoTool Intervention (MBSR + HT education)
Description: OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oncotool Control (health +HT education)
Description: OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study: NCT00947505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb 2009, 7 Beam
Description: Device application 3 times week (non-consecutive days), for 26 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb
Description: Device application 3 times week (non-consecutive days), for 26 weeks
Study: NCT00096161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV
Study: NCT02015221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Action Pneumatic Compression Device
Description: A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compression Garments
Description: Compression stockings with a 30-40mmHg level of compression.
Study: NCT03894371

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermage FLX
Description: Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
Study: NCT00995566

Intervention type: DRUG
Intervention: Sitaxentan sodium
Description: Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
Study: NCT02411747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directed self-regulated simulation training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directed self-regulated simulation training
Study: NCT03717272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0117
Description: AEF0117 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AEF0117
Description: AEF0117 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Study: NCT03158220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V503
Description: V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
Study: NCT03155646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
Study: NCT03717272

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Study: NCT00167856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venalafaxine hydrochloride
Description: Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venalafaxine hydrochloride
Description: Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
Study: NCT06421129

Intervention type: PROCEDURE
Intervention: anal fistula surgery
Description: anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement

Intervention type: PROCEDURE
Intervention: anal fistula surgery
Description: anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
Study: NCT00368290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 300mg a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Weekly cognitive behavioral therapy sessions for a period of 8 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
Study: NCT02727231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florence D2A or similar closed loop glucose control system
Description: Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII with CGM
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
Study: NCT04240080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein® Veinfinder
Description: Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
Study: NCT01150344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone (atovaquone + proguanil combination)
Description: 4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RIAMET (artemether + LUMEFANTRIN combination)
Description: 4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
Study: NCT02979860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration 90 min
Description: Sleep duration: time in bed increased by 90 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration 45 min
Description: Sleep duration: time in bed increased by 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep timing
Description: Sleep timing: bed time kept consistent
Study: NCT02615626

Intervention type: PROCEDURE
Intervention: Non-surgical Periodontal Treatment.
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis

Intervention type: PROCEDURE
Intervention: Non-surgical Periodontal Treatment.
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis

Intervention type: PROCEDURE
Intervention: Non-surgical Periodontal Treatment.
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
Study: NCT03320876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib
Description: one filgotinib oral tablet once daily.
Study: NCT02874170

Intervention type: OTHER
Group type: OTHER
Intervention: Spectroscopy magnetic resonance of phosphorus 31

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectroscopy magnetic resonance of phosphorus 31
Study: NCT01816451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running training
Description: The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running training
Description: The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
Study: NCT00002501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT03508791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arterial carbon dioxide monitoring
Description: Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arterial carbon dioxide monitoring
Description: Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-tidal carbon dioxide monitoring
Description: End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-tidal carbon dioxide monitoring
Description: End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous carbon dioxide monitoring
Description: Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous carbon dioxide monitoring
Description: Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
Study: NCT02226744

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focused Breathing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focused Breathing
Study: NCT00755300

Intervention type: PROCEDURE
Intervention: Measurement of total thrombolic load
Description: A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load

Intervention type: PROCEDURE
Intervention: Measurement of total thrombolic load
Description: A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
Study: NCT03712709

Intervention type: DIAGNOSTIC_TEST
Intervention: Truenat MTB
Description: The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.

Intervention type: DIAGNOSTIC_TEST
Intervention: Truenat MTB
Description: The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.